Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in patients with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity, and since 2024 for cardiovascular risk reduction in patients with established cardiovascular disease and overweight or obesity
Recent Findings Originally developed for glycemic control in T2DM, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now being utilized for a range of additional diseases and conditions
J Mayo Clin Proc 78(4):447456 Hoang SH, Lam EM, Dao H (2024) Computational assessment of gut microbiota metabolite enterolactone as a promising A42 inhibitor in Alzheimers disease
It boosts testosterone levels by removing harmful compounds, like free radicals and oxidation, from the body
That being said, not everyone who is interested in semaglutide will qualify for a prescription
Food and Drug Administration ("FDA") and have not been evaluated by the FDA for safety, efficacy, or quality